A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)

To join this study, people generally need to be at least 18 years old and have an advanced solid cancer that has either spread or cannot be removed by surgery. This cancer shouldn't be a type of bowel cancer. Importantly, their cancer must have progressed despite having received standard treatments already, and a test must show that their cancer has a specific genetic change called the KRAS G12C mutation.

There are also some reasons why someone might not be able to join. For example, if they have serious heart problems that are not controlled, or if they have other cancers that are growing or have needed recent treatment. People with active infections needing strong medicines, or cancers that have spread to their brain, would also not be able to participate. Also, if someone has not fully recovered from recent major surgery, they might not be able to join.

If you join this study, you'll receive either calderasib alone or calderasib with cetuximab, depending on which group you're assigned to. This will involve regular visits to the hospital or clinic for your medication and various tests. These tests might include blood tests, scans (like CT or MRI) to check your cancer, and physical examinations. The doctors and nurses will closely monitor your health and any side effects you might experience. They’ll also ask you about how you're feeling and any symptoms you have. The exact number of visits and the full duration of your participation will be explained in detail by the study team, but it will involve ongoing assessment and treatment for as long as the treatment is beneficial or until side effects make it necessary to stop.